John Bailey
Psychiatry · Tallahassee, FLNPI 1437115813
Payments from drug & device makers
Across 92 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$472
- Otsuka America Pharmaceutical, Inc.$257
- AbbVie$141
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$110
- Neurocrine Biosciences, Inc.$88
- Neuronetics, Inc.$86
- plus $507 from 14 others
What the payments were for
- Food & beverage$1,50891%
- Education$1539%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 28 | $472 |
| Otsuka America Pharmaceutical, Inc. | 11 | $257 |
| AbbVie(2 entities) | 9 | $141 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $110 |
| Neurocrine Biosciences, Inc. | 6 | $88 |
| Neuronetics, Inc. | 1 | $86 |
| Lundbeck LLC | 5 | $73 |
| Teva Pharmaceuticals USA, Inc. | 5 | $66 |
| Sunovion Pharmaceuticals Inc. | 1 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $59 |
| Novo Nordisk | 2 | $44 |
| Alkermes, Inc. | 3 | $41 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| Shire North American Group Inc | 2 | $26 |
| Adlon Therapeutics L.p. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $13 |
| Bausch Health US, LLC | 1 | $12 |
How this compares
$1,662 in reported general payments places this provider in the 65th percentile of 2,059 psychiatry providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 90 | $432,624 |
| FanaptIloperidone | 73 | $143,025 |
| IngrezzaValbenazine Tosylate | 11 | $81,583 |
| RexultiBrexpiprazole | 14 | $25,317 |
| VraylarCariprazine Hcl | 18 | $20,397 |
| CaplytaLumateperone Tosylate | 12 | $19,406 |
| Divalproex Sodium | 311 | $18,679 |
| Lurasidone Hcl | 143 | $12,347 |
| Divalproex Sodium ErDivalproex Sodium | 104 | $12,162 |
| Quetiapine Fumarate | 412 | $11,477 |
| Clozapine | 66 | $8,813 |
| Aripiprazole | 252 | $7,880 |
| Lamotrigine | 244 | $5,535 |
| Gabapentin | 179 | $5,368 |
| Naltrexone Hcl | 45 | $3,798 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $66 | $432,62490 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $472 | $143,02573 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $88 | $81,58311 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $257 | $25,31714 claims |
| AbbVieVraylar | $141 | $20,39718 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $110 | $19,40612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Tallahassee
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
- Olga LapeyraLauderhill$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.